Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
OBJECTIVE
To investigate if there is a difference in response to tuberculosis treatment between HIV seronegative and HIV seropositive patients following two months of intensive phase tuberculosis treatment.


METHODS
Prospective cohort study.


METHODS
St. Francis Leprosy Centre, south-east Uganda.


METHODS
Four hundred fifty seven patients with never previously treated sputum smear-positive tuberculosis admitted during a two-year period in 1991/1993.


METHODS
Intensive phase treatment with streptomycin, isoniazid, rifampicin and pyrazinamide.


METHODS
Sputum conversion from a positive to a negative smear at eight weeks of treatment.


RESULTS
HIV seropositivity prevalence was 28%. Among HIV seronegative patients, conversion to a negative smear status occurred in 76% persons compared to 78% in HIV seropositive patients. This difference was not statistically significant (OR = 0.9; 95% CI, 0.6-1.5). HIV seropositive patients, however, were more likely to die (p = 0.017). A high prevalence of resistance to isoniazid and streptomycin was found. Isoniazid resistance was more likely in HIV seronegative patients with M. tuberculosis strains compared to HIV seropositive persons (p < 0.005). Initial resistance to antituberculosis drugs did not have a significant effect on smear conversion.


CONCLUSIONS
This study demonstrates that HIV-seropositive status is not a principal factor in delaying sputum conversion among patients receiving intensive phase tuberculosis treatment.
Bwire
R
R
St. Francis Leprosy Centre, Buluba, Uganda.
Borgdorff
M W
MW
Sticht-Groh
V
V
Rieder
H L
HL
Kawuma
H J
HJ
Bretzel
G
G
Rüsch-Gerdes
S
S
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000382:microbiology* / Q000401:mortality; D000293:Adolescent; D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use*; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005260:Female; D018023:HIV Seronegativity; D015528:HIV Seroprevalence; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011718:Pyrazinamide / Q000627:therapeutic use*; D012293:Rifampin / Q000627:therapeutic use*; D013183:Sputum / Q000382:microbiology*; D013307:Streptomycin / Q000627:therapeutic use*; D016019:Survival Analysis; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000382:microbiology* / Q000401:mortality; D014454:Uganda / Q000453:epidemiology
D000995:Antitubercular Agents; D011718:Pyrazinamide; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin